Yoshiji Hantani

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 12

Top Venues

Journal of medicinal chemistry

SLAS discovery : advancing life sciences R & D

Biochemistry

ACS medicinal chemistry letters

Japan Tobacco (Japan)

Kyoto Prefectural University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Japan Tobacco (Japan)

Japan

Director :: Central Pharmaceutical Research Institute

Education History

Kyoto Prefectural University

Japan

PHD :: Faculty of Life and Environmental Sciences

Okayama University

Japan

MSC :: Graduate School of Medicine

Okayama University

Japan

BSC :: Faculty of Pharmaceutical Sciences

Publications

Kazuki Otake, Yoshinori Hara, Minoru Ubukata, Masafumi Inoue, Noboru Nagahashi, Dai Motoda, Naoki Ogawa, Yoshiji Hantani, Rie Hantani, Tsuyoshi Adachi, Akihiro Nomura, Keishi Yamaguchi, Mariko Maekawa, Hideaki Mamada, Takahisa Motomura, Motohide Sato, Kazuhito Harada
Correction to "Optimization Efforts for Identification of Novel Highly Potent Keap1-Nrf2 Protein-Protein Interaction Inhibitors". Journal of medicinal chemistry (2024)
Kazuki Otake, Yoshinori Hara, Minoru Ubukata, Masafumi Inoue, Noboru Nagahashi, Dai Motoda, Naoki Ogawa, Yoshiji Hantani, Rie Hantani, Tsuyoshi Adachi, Akihiro Nomura, Keishi Yamaguchi, Mariko Maekawa, Hideaki Mamada, Takahisa Motomura, Motohide Sato, Kazuhito Harada
Optimization Efforts for Identification of Novel Highly Potent Keap1-Nrf2 Protein-Protein Interaction Inhibitors. Journal of medicinal chemistry 67 (5) (2024)
Kazuki Otake, Yoshinori Hara, Minoru Ubukata, Masafumi Inoue, Noboru Nagahashi, Dai Motoda, Naoki Ogawa, Yoshiji Hantani, Rie Hantani, Tsuyoshi Adachi, Akihiro Nomura, Keishi Yamaguchi, Mariko Maekawa, Hideaki Mamada, Takahisa Motomura, Motohide Sato, Kazuhito Harada
Optimization Efforts for Identification of Novel Highly Potent Keap1-Nrf2 Protein-Protein Interaction Inhibitors. Journal of medicinal chemistry 67 (5) (2024)
Kazuki Otake, Yoshinori Hara, Minoru Ubukata, Masafumi Inoue, Noboru Nagahashi, Dai Motoda, Naoki Ogawa, Yoshiji Hantani, Rie Hantani, Tsuyoshi Adachi, Akihiro Nomura, Keishi Yamaguchi, Mariko Maekawa, Hideaki Mamada, Takahisa Motomura, Motohide Sato, Kazuhito Harada
Optimization Efforts for Identification of Novel Highly Potent Keap1-Nrf2 Protein-Protein Interaction Inhibitors. Journal of medicinal chemistry (2024)
Kazuki Otake, Yoshinori Hara, Minoru Ubukata, Masafumi Inoue, Noboru Nagahashi, Dai Motoda, Naoki Ogawa, Yoshiji Hantani, Rie Hantani, Tsuyoshi Adachi, Akihiro Nomura, Keishi Yamaguchi, Mariko Maekawa, Hideaki Mamada, Takahisa Motomura, Motohide Sato, Kazuhito Harada
Optimization Efforts for Identification of Novel Highly Potent Keap1-Nrf2 Protein-Protein Interaction Inhibitors. Journal of medicinal chemistry 67 (5) (2024)
Kazuki Otake, Minoru Ubukata, Noboru Nagahashi, Naoki Ogawa, Yoshiji Hantani, Rie Hantani, Tsuyoshi Adachi, Akihiro Nomura, Keishi Yamaguchi, Mariko Maekawa, Hideaki Mamada, Takahisa Motomura, Motohide Sato, Kazuhito Harada
Methyl and Fluorine Effects in Novel Orally Bioavailable Keap1-Nrf2 PPI Inhibitor. ACS medicinal chemistry letters 14 (5) (2023)
Wataru Asano, Kenji Yamanaka, Yasunori Ohara, Toru Uhara, Satoki Doi, Takuya Orita, Tomoko Iwanaga, Tsuyoshi Adachi, Shingo Fujioka, Tatsuo Akaki, Kazutaka Ikegashira, Yoshiji Hantani
Fragment-Based Discovery of Novel VE-PTP Inhibitors Using Orthogonal Biophysical Techniques. Biochemistry (2023)
Kazuki Otake, Minoru Ubukata, Noboru Nagahashi, Naoki Ogawa, Yoshiji Hantani, Rie Hantani, Tsuyoshi Adachi, Akihiro Nomura, Keishi Yamaguchi, Mariko Maekawa, Hideaki Mamada, Takahisa Motomura, Motohide Sato, Kazuhito Harada
Methyl and Fluorine Effects in Novel Orally Bioavailable Keap1-Nrf2 PPI Inhibitor. ACS medicinal chemistry letters 14 (5) (2023)
Seiji Kawashita, Koichi Aoyagi, Kyoko Fukushima, Rie Hantani, Shiori Naruoka, Atsuo Tanimoto, Yuji Hori, Yukiyo Toyonaga, Hiroshi Yamanaka, Susumu Miyazaki, Yoshiji Hantani
SAR study of small molecule inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction. Chemical biology & drug design 98 (5) (2021)
Kenji Yamanaka, Yu Takahashi, Yuya Azuma, Yoshiji Hantani
Assay Development and Screening for the Identification of Ganglioside GM3 Synthase Inhibitors. Biochemistry 59 (12) (2020)
Rie Hantani, Yu Takahashi, Tomohiro Sotani, Yoshiji Hantani
Identification of Novel Phospholipid Transfer Protein Inhibitors by High-Throughput Screening. SLAS discovery : advancing life sciences R & D 24 (5) (2019)
Rie Hantani, Saya Hanawa, Shohei Oie, Kayo Umetani, Toshihiro Sato, Yoshiji Hantani
Identification of a New Inhibitor That Stabilizes Interleukin-2-Inducible T-Cell Kinase in Its Inactive Conformation. SLAS discovery : advancing life sciences R & D 24 (8) (2019)

Yoshiji Hantani.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yoshiji Hantani